Loading
institutionsInstitution
Society for Immunotherapy of Cancer
The society of cancer immunologists and immuno-oncologists, whose annual meeting, guidelines and immune-related adverse event management resources track the immunotherapy era.
Also called: SITCInternational Society for Biological Therapy of CanceriSBTc
Overview
Founded in 1984 as the Society for Biological Therapy and renamed in 2010, SITC grew with checkpoint inhibitors into the main professional home of cancer immunotherapy. Its annual meeting each November presents cellular therapy, checkpoint, vaccine and bispecific data and translational immunology; it publishes the Journal for ImmunoTherapy of Cancer, issues Cancer Immunotherapy Guidelines by disease and on immune-related toxicities, and runs the Immuno-Oncology Biomarkers task forces, the Sparkathon early-career programme and the SITC Cancer Immunotherapy Winter School. SITC also produces the primer on CAR-T toxicity management and works with FDA on regulatory science for immunotherapy combinations.
Location
Milwaukee, WI, US
Type
consortium
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#186 · 30 points (0 Newsweek + 0 NCI + 30 from 15 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to Society for Immunotherapy of Cancer, including child institutions. 6 works · 1 citations · 100% open access · 17% clinical trials · 0% reviews.
Oncology works per year
12022
12023
12024
12025
22026
Most works
- Anjishnu Banerjee2 works
- Sailaja Kamaraju1 works
- William A. Hall1 works
- Koramit Suppipat1 works
- Fauzia Qureshi1 works
- Supannikar Tawinwung1 works
- Mandana Kamgar1 works
- Siran M. Koroukian1 works
- Bradley A. Erickson1 works
- Chantiya Chanswangphuwana1 works
Most cited
- SITC Annual Meeting
- Journal for ImmunoTherapy of Cancer
- Cancer Immunotherapy Guidelines (disease and toxicity)
- Biomarker task forces
- Winter School and Sparkathon
Howard L. Kaufman
Surgical Oncologist, Massachusetts General Hospital; Chief Medical Officer, Ankyra Therapeutics
Oncolytic virus therapyMelanomaIntratumoural immunotherapy
Led OPTiM, the trial that made talimogene laherparepvec the first approved oncolytic virus therapy.
Jason J. Luke
Director, Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center
MelanomaAdjuvant immunotherapyEarly-phase immunotherapy
Led KEYNOTE-716, which extended adjuvant pembrolizumab to high-risk stage II melanoma.
Sandra Demaria
Vice President (2025-2026)
Radiation and immunotherapy combinationsTumour immunologyBreast cancer
Weill Cornell pathologist-immunologist known for radiation-immunotherapy research; SITC Vice President.
Patrick Hwu
President and Chief Executive Officer
Tumour immunologyAdoptive cell therapyMelanoma
Patrick Hwu is an immunotherapy pioneer who trained with Rosenberg and now leads Moffitt.
Drew M. Pardoll
Director, Bloomberg~Kimmel Institute for Cancer Immunotherapy
Tumour immunologyPD-1 pathwayCancer vaccines
Immunologist who helped define the PD-1 pathway's role in cancer and built one of the largest immunotherapy institutes.
F. Stephen Hodi
Director, Melanoma Center and Center for Immuno-Oncology
MelanomaCheckpoint inhibitorsImmuno-oncology
First author of the 2010 ipilimumab trial that proved immunotherapy could extend survival in melanoma.
Suzanne L. Topalian
Bloomberg~Kimmel Professor of Cancer Immunotherapy; Associate Director, Bloomberg~Kimmel Institute
PD-1 blockadeMelanomaNeoadjuvant immunotherapy
Suzanne Topalian led the first nivolumab trials showing PD-1 blockade works across several cancers.
Similar pages
- PersonMichael Bloomberg
Shares Suzanne L. Topalian, Drew M. Pardoll, No one can predict who responds to immunotherapy, Immune checkpoint inhibitors.
- Key paperTopalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer
Shares Suzanne L. Topalian, Drew M. Pardoll, F. Stephen Hodi, Immune-related adverse events (irAEs).
- RoadmapImmunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity
Shares TIL therapy, Oncolytic viruses, Hot vs cold tumours, Personalised neoantigen (mRNA) vaccines.
- TermImmunotherapy
Shares TIL therapy, Immune-related adverse events (irAEs), Oncolytic viruses, Hot vs cold tumours.
- Key paperASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors
Shares ICANS (neurotoxicity), Immune-related adverse events (irAEs), American Society of Clinical Oncology (ASCO), Cytokine release syndrome (CRS).
- IdeaClear the suppressive neutrophils out of pancreatic tumours first
Shares Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy, Immune checkpoint inhibitors.
- IdeaDe-acidify the tumour so T cells can work in it
Shares Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy, Immune checkpoint inhibitors.
- IdeaMake every cold tumour hot: a coordinated programme to reprogramme immune-excluded tumours
Shares Oncolytic viruses, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy.